Paradigm Biopharmaceuticals Ltd
(ASX:PAR)
announced that its Phase 3 knee osteoarthritis clinical trial met the pre-defined futility criterion at interim analysis, leading to the appointment of voluntary administrators effective 29 September 2026, as detailed in the company’s quarterly activities report for the period ending 30 September 2026.
Key Points
- On 23 September 2026, the independent Data Safety Monitoring Board confirmed that interim efficacy results in PARA_OA_012 fell below the pre-specified continuation threshold, triggering the futility…